Forward Pharma A/S (NASDAQ:FWP) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

FWP has been the topic of several other reports. BidaskClub upgraded shares of Forward Pharma A/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research cut shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, November 28th. Finally, Jefferies Group reiterated a “hold” rating and issued a $6.00 target price (up from $5.00) on shares of Forward Pharma A/S in a research note on Wednesday, September 27th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Forward Pharma A/S has a consensus rating of “Hold” and an average price target of $17.00.

Shares of Forward Pharma A/S (NASDAQ:FWP) traded up $0.03 during mid-day trading on Friday, hitting $4.14. 15,056 shares of the company were exchanged, compared to its average volume of 32,529. Forward Pharma A/S has a 12 month low of $4.02 and a 12 month high of $33.00.

Several large investors have recently modified their holdings of the company. Alliancebernstein L.P. bought a new position in shares of Forward Pharma A/S in the 2nd quarter worth $203,000. OxFORD Asset Management LLP bought a new position in shares of Forward Pharma A/S in the 2nd quarter worth $210,000. Cowen Inc. bought a new position in shares of Forward Pharma A/S in the 2nd quarter worth $225,000. Alps Advisors Inc. bought a new position in shares of Forward Pharma A/S in the 2nd quarter worth $866,000. Finally, Eqis Capital Management Inc. increased its holdings in shares of Forward Pharma A/S by 280.9% in the 3rd quarter. Eqis Capital Management Inc. now owns 76,867 shares of the biotechnology company’s stock worth $467,000 after buying an additional 56,689 shares during the last quarter. 21.57% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/forward-pharma-as-fwp-stock-rating-upgraded-by-valuengine.html.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.